Close  

FDA permanently revokes Dengvaxia’s certificate of registration

/ 01:39 PM February 19, 2019
FDA permanently revokes Dengvaxia’s certificate of registration

VACCINE SCARE Former officials of the previous administration are facing criminal and administrative charges for the aborted Dengvaxia vaccination program, which caused a massive health scare. The vaccine maker, Sanofi Pasteur, refunded the government P1.16 billion for unused Dengvaxia doses. —INQUIRER FILE PHOTO

MANILA, Philippines — The Food and Drug Administration (FDA) has permanently revoked the certificates of product registration (CPRs) it previously issued to Dengvaxia products after its manufacturer failed to submit post-approval commitment documents.

FDA Director General Nela Charade Puno on Tuesday cited French pharmaceutical firm Sanofi Pasteur, Inc.’s disregard of the agency’s rules and regulations as reason for the cancellation of its CPRs.

ADVERTISEMENT

Sanofi Pasteur’s “brazen defiance of the FDA’s directives and its continued failure to comply leaves us no other recourse but to impose the maximum penalty of revocation of the CPRs covering the Dengvaxia products,” Puno said in a statement.

According to FDA, it has ordered Sanofi Pasteur on December 21, 2018 to “immediately surrender” the original CPRs of Dengvaxia products – Dengue Tetravalent (Live Attenuated), Dengvaxia MD and Dengue Tetravalent Vaccine (Live Attenuated) (Dengvaxia).

FEATURED STORIES

Moreover, FDA said Sanofi Pasteur has yet to submit and comply with its post marketing authorization requirements as of December 17, 2018.

To recall, FDA initially suspended the CPR of Dengvaxia in 2017, and directed Sanofi Pasteur to halt the sale, distribution, or marketing of Dengvaxia.

Dengvaxia was also pulled out from the market pending compliance with the directives of FDA.

With the revocation of CPRs for Dengvaxia products, Sanofi Pasteur is prohibited from importing, selling or distributing Dengue Tetravalent (Live Attenuated), Dengvaxia MD and Dengue Tetravalent Vaccine (Live Attenuated) (Dengvaxia), FDA said.

The Center for Drug Regulation and Research was then instructed to defer the processing of any submission and application made by Sanofi Pasteur regarding Dengvaxia and Dengvaxia-MD due to the cancellation of its CPRs.

The Department of Health launched its anti-dengue inoculation drive in 2016, and administered Dengvaxia vaccine to over 830,000 adults and children in Central Luzon, Calabarzon, Metro Manila, and Cebu under the program.

Around a year later, Sanofi Pasteur issued a statement saying Dengvaxia vaccine may increase the risk of severe dengue in patients who received it without previous exposure to the mosquito-borne disease. /kga

ADVERTISEMENT

RELATED STORIES

No confirmed death directly caused by Dengvaxia — DOH

Ex-President Aquino, 2 others face charges for Dengvaxia fiasco

Read Next
LATEST STORIES
MOST READ
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: dengue, Dengvaxia, FDA, Local news, Nation, national news, news, Philippine news updates, Sanofi Pasteur, vaccine
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2019 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.